Philadelphia chromosome-positive acute lymphoblastic leukemia

Yuichi Kodama, Hiroyuki Shimada

研究成果: Chapter

抄録

In the treatment of childhood Ph+ALL, TKI-combined chemotherapy has become the standard option, and HSCT in first remission is no longer an absolute indication. However, pediatric Ph+ALL is still a refractory leukemia, and 5-year EFS in children without HSCT in first remission was only 55-60% because of treatment-related death and post-chemotherapy relapse. Further improvement in clinical outcomes may require intensified targeted therapy in combination with low-intensity chemotherapy and/or immune antibody therapy with reduced toxicity. Continuing to address these challenges in prospective clinical studies will change childhood Ph+ALL from refractory leukemia to more manageable leukemia in the future.

本文言語English
ホスト出版物のタイトルPediatric Acute Lymphoblastic Leukemia
出版社Springer Singapore
ページ93-99
ページ数7
ISBN(電子版)9789811505485
ISBN(印刷版)9789811505478
DOI
出版ステータスPublished - 2019 1 1

ASJC Scopus subject areas

  • Medicine(all)

フィンガープリント 「Philadelphia chromosome-positive acute lymphoblastic leukemia」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル